Stoke Therapeutics (STOK) Non Operating Income (2019 - 2026)

Stoke Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 17.07% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $14.2 million, a 6.94% increase from a year earlier, with the FY2025 full-year figure at $13.7 million, up 10.6% from the prior year.
• Non Operating Income fell to $3.4 million in Q1 2026 per STOK's latest filing, from $3.6 million in the prior quarter.
• Across five years, Non Operating Income topped out at $3.8 million in Q2 2025 and bottomed at $104000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $2.7 million (2023), against an average of $2.5 million.
• Across the five-year window, Non Operating Income soared 4082.35% in 2022 and retreated 6.85% in 2024, its largest moves.
• Year by year, Non Operating Income stood at $1.4 million in 2022, then soared by 94.09% to $2.6 million in 2023, then grew by 20.66% to $3.2 million in 2024, then rose by 12.39% to $3.6 million in 2025, then decreased by 4.18% to $3.4 million in 2026.
• Per Business Quant, the three latest STOK Non Operating Income figures stand at $3.4 million (Q1 2026), $3.6 million (Q4 2025), and $3.5 million (Q3 2025).